




The Building Block for Conjugates (Antibody & Payload-Linker)

Catalog Products

mAb

Product Code	Product Name	Target
PT-1001	Trastuzumab	HER2
PT-1002	Disitamab	HER2
PT-1003	Sacituzumab	TROP2
PT-1004	Datopotamab	TROP2
PT-1005	Inebilizumab	CD19
PT-1006	Denintuzumab	CD19
PT-1007	Daratumumab	CD38
PT-1008	Moxetumomab	CD22
PT-1009	Inotuzumab	CD22
PT-1010	Enfortumab	Nectin-4
PT-1011	Vobramitamab	B7-H3
PT-1012	Naratuximab	CD37

BsAb

Product Code	Product Name	Target
PT-2001	Faricimab	Ang-2/VEGF-A
PT-2002	Glofitamab	CD3/CD20
PT-2003	Cadonilimab	PD1/CTLA-4
PT-2004	Blinatumomab	CD3/CD19
PT-2005	Emicizumab	FIXa/FX
PT-2006	Talquetamab	CD3/GPRC5D
PT-2007	Elranatamab	BCMA/CD3
PT-2008	Epcoritamab	CD3/CD20
PT-2009	Tedistanmab	BCMA/CD3
PT-2010	Ozoralizumab	TNF- α /HAS
PT-2011	Mosunetuzumab	CD3/CD20
PT-2012	Tebentafusp	CD3/gp100
PT-2013	Amivantamab	EGFR/c-Met

Payload-Linker

Product Code	Product Name	CAS	Structure	Chemical Name
PT-3001	MC-VC-PAB-PNP	159857-81-5		4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl(4-nitrophenyl) carbonate
PT-3002	Fmoc-Val-Cit-PAB- PNP	863971-53-3		(9H-fluoren-9-yl)methyl((S)-3-methyl-1-((S)-1-((4-((4-nitrophenoxy)carbonyloxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate
PT-3003	Fmoc-Val-Cit-PAB- OH	159858-22-7		(9H-fluoren-9-yl)methyl((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
PT-3004	Dil.HCl	120205-48-3		(3R,4S,5S)-tert-butyl3-Methoxy-5-Methyl-4-(Methylamino)heptanoate hydrochloride
PT-3005	Boc-Dap DCHA	1369427-40-6		N-Boc-Dolaproline DCHA
PT-3006	MMAE	474645-27-7		(S)-N-((3R,4S,5S)-1-((R)-2-((1R,2R)-3-((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide
PT-3007	Exatecan Intermediates (94-5)	110351-94-5		(S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyran[3,4-f]indolizine-3,6,10(4H)-trione
PT-3008	Exatecan Intermediates (31-6)	182182-31-6		N-(8-amino-6-fluoro-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide
PT-3009	Exatecan mesylate	169869-90-3		(1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione methanesulfonate
PT-3010	MAC glucuronide linker-2	229977-57-5		(2S,3R,4S,5S,6S)-2-(2-amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
PT-3011	MC-Val-Ala-PAB- PNP	1639939-40-4		4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)propanamido)benzyl(4-nitrophenyl)carbonate
PT-3012	MC-VC-PAB- MMAE	646502-53-6		4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methylamino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate

Payload-Linker

Product Code	Product Name	CAS	Structure	Chemical Name
PT-3013	MAL-di-EG-OPFP	1807512-47-5		
PT-3014	MAL-tri-EG-OH	2055353-75-6		
PT-3015	MAL-tetra-EG-OPFP	1415800-42-8		
PT-3016	N3-tri-EG-OPFP	1393330-37-4		
PT-3017	N3-tetra-EG-OPFP	1353012-00-6		
PT-3018	ALD-tetra-EG-Osu	1353011-74-1		
PT-3019	ALD-di-EG-OPFP	2101206-60-2		
PT-3020	PHA-di-EG-Osu	2101206-31-7		
PT-3020	b-D-Glucopyranosiduronic acid	1353003-35-6		

PORTON

Please note that some of the products mentioned above are still under patent protection and can only be used for R&D as permitted under the specific legal frameworks: 35 U.S.C. §271(e)(1) in the United States; Article 69, Paragraph 1 of the Patent Act in Japan; Directive 2004/27/EC of the European Parliament and Council of 31 March 2004; or Article 69(5) of the Patent Law in the People's Republic of China. We will not manufacture, sell, offer for commercial sale, or distribute these products in or to regions where substance patents are still in effect. Additionally, we cannot be held responsible if the use of any aforementioned products results in patent infringement within your country.

For any custom product requests, please contact us!



LinkedIn

© PORTON, V1 2024

Porton Pharma Solutions Ltd.
business@portonpharma.com
www.portonpharma.com